Ceribell, Inc. (CBLL): Cost of Revenue
$10.79M
Year ended 2025-12-31
$11.32M
Trailing 12 months to 2026-06-30
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.79M | +24.1% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $8.69M | +23.1% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $7.06M | n/a | 2025-02-25, From 2023-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | 2025-12-31 | $10.79M | +24.1% |
| Vaso Corp (VASO) | 2025-12-31 | $34.42M | -0.8% |
| Biolife Solutions Inc (BLFS) | 2025-12-31 | $34.10M | +38.9% |
| Electromed, Inc. (ELMD) | 2026-06-30 | $15.83M | +12.9% |
| Outset Medical, Inc. (OM) | 2025-12-31 | $72.72M | -3.2% |
| Iridex Corp (IRIX) | 2026-01-03 | $33.45M | +14.7% |
| Axogen, Inc. (AXGN) | 2025-12-31 | $57.85M | +27.5% |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $15.31M | +24.2% |
| electroCore, Inc. (ECOR) | 2025-12-31 | $4.24M | +12.1% |
Compare CBLL, VASO, BLFS, ELMD side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗